Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Rhea-AI Summary
Hemab Therapeutics (Nasdaq: COAG) priced an upsized initial public offering of 16,750,000 shares at $18.00 per share, with a 30-day underwriter option for an additional 2,512,500 shares.
Gross proceeds are expected to be approximately $301.5 million before underwriting discounts, and trading on the Nasdaq Global Select Market is expected to begin on May 1, 2026 with closing on or about May 4, 2026.
Positive
- Priced IPO of 16,750,000 shares at $18.00 per share
- Expected gross proceeds of approximately $301.5 million
- Listing on Nasdaq Global Select expected to begin on May 1, 2026
Negative
- Underwriters have a 30-day option for up to 2,512,500 additional shares, increasing potential dilution
- Gross proceeds exclude underwriting discounts, commissions and offering expenses, reducing net proceeds
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of
Hemab’s common stock is expected to begin trading on the Nasdaq Global Select Market on Friday, May 1, 2026 under the ticker symbol “COAG.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, are expected to be approximately
Goldman Sachs & Co. LLC, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been filed with the Securities and Exchange Commission and was declared effective on April 30, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the closing date of the initial public offering, the commencement of trading on the Nasdaq Global Select Market and the anticipated gross proceeds from the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Hemab’s management team and speak only as of the date hereof, and Hemab specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Media:
Deerfield
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com
